MCID: CND004
MIFTS: 57

Candidiasis

Categories: Blood diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Candidiasis

MalaCards integrated aliases for Candidiasis:

Name: Candidiasis 12 74 54 43 15 71 32
Systemic Candidiasis 12 52 71
Invasive Candidiasis 52 3 71
Disseminated Candidiasis 12 54
Systemic Candida Infections 52
Candidiasis, Invasive 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1508
ICD9CM 34 112 112.9
MeSH 43 D002177
NCIt 49 C26711
SNOMED-CT 67 78048006
ICD10 32 B37 B37.9
UMLS 71 C0006840 C0153252 C1609535

Summaries for Candidiasis

CDC : 3 Invasive candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Unlike Candida infections in the mouth and throat (also called "thrush") or vaginal "yeast infections," which are localized to one part of the body, invasive candidiasis is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body.1 Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on the skin without causing any problems.2 However, in certain patients who are at risk, Candida can enter the bloodstream or internal organs and cause an infection. A Candida bloodstream infection, also called candidemia, is the most common form of invasive candidiasis.1 In the United States, candidemia is one of the most common causes of bloodstream infections in hospitalized patients,3–4 and it often results in long hospital stays and death. It is also responsible for high medical costs.5 Antifungal medication can treat invasive candidiasis. Certain patients such as those with cancer or bone marrow or organ transplants might receive antifungal medication to prevent invasive candidiasis.6

MalaCards based summary : Candidiasis, also known as systemic candidiasis, is related to vulvovaginal candidiasis and esophageal candidiasis. An important gene associated with Candidiasis is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Anidulafungin and Voriconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and skin, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons.

NIH Rare Diseases : 52 Systemic candidiasis includes a spectrum of yeast infections caused by different species (types) of Candida . It is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. Although there are over 200 species of Candida , five different species of Candida cause 90% of systemic candidiasis. The most common form of this invasive yeast infection is when Candida enters the bloodstream (candidemia). Signs of candidemia include fever and chills that do not improve with antibiotics . Symptoms of other types of systemic candidiasis depend on the organ or system which is infected. Systemic candidiasis is the most common fungal infection among hosptilized people in high-income countries, including the United States. Diagnosis can be difficult, especially when the Candida is not found in the bloodstream. Treatment usually includes consists of oral or intravenous (IV) antifungal medications.

Wikipedia : 74 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Candidiasis

Diseases in the Candidiasis family:

Candidiasis, Familial, 1 Candidiasis, Familial, 2
Candidiasis, Familial, 3 Candidiasis, Familial, 4
Candidiasis, Familial, 6 Candidiasis, Familial, 8
Candidiasis, Familial, 9

Diseases related to Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 728)
# Related Disease Score Top Affiliating Genes
1 vulvovaginal candidiasis 34.9 SKAP2 DEFB4A CLEC7A CARD9
2 esophageal candidiasis 34.7 CARD9 AIRE
3 cutaneous candidiasis 34.2 IL17RC IL17RA IL17F IL17A CLEC7A CARD9
4 oral candidiasis 33.8 STAT1 SKAP2 IL17RA IL17F IL17A HTN3
5 chronic mucocutaneous candidiasis 33.3 TRAF3IP2 STAT1 IL22 IL17RC IL17RA IL17F
6 candida glabrata 32.8 SKAP2 HTN3 APCS
7 autoimmune polyendocrine syndrome type 1 32.5 IL22 IL17RA IL17F IL17A CLEC7A CARD9
8 cryptococcosis 31.4 IL17A IL10 CLEC7A
9 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.3 IL17A IL10 AIRE
10 dermatophytosis 31.1 IL17A DEFB4A CLEC7A CARD9
11 autoimmune disease 31.0 IL22 IL17F IL17A IL10 AIRE
12 lichen planus 31.0 IL17A IL10 DEFB4A
13 autoimmune polyendocrine syndrome 30.9 IL22 IL17A IL10 AIRE
14 denture stomatitis 30.9 DEFB4A CLEC7A
15 sporotrichosis 30.7 IL10 CLEC7A CARD9
16 tinea pedis 30.7 CLEC7A CARD9
17 pneumonia 30.7 IL22 IL17A IL10 DEFB4A
18 blastomycosis 30.6 IL17A CLEC7A CARD9
19 alopecia areata 30.6 IL17A IL10 AIRE
20 coccidioidomycosis 30.5 STAT1 IL17A CLEC7A CARD9
21 dermatitis, atopic 30.5 STAT1 IL17F IL17A IL10 DEFB4A
22 tinea cruris 30.4 DEFB4A CARD9
23 salmonellosis 30.4 STAT1 IL10 DEFB4A
24 colitis 30.3 IL22 IL17RA IL17A IL10
25 psoriasis 30.3 TRAF3IP2 IL22 IL17F IL17A IL10 DEFB4A
26 neurosyphilis 30.3 IL17A IL10
27 periodontitis 30.1 IL17A IL10 DEFB4A
28 mycetoma 30.1 IL17A IL10 CHIT1
29 tinea corporis 30.0 DEFB4A CARD9
30 mycobacterium tuberculosis 1 30.0 STAT1 IL17A IL10 CLEC7A
31 vaginal disease 30.0 SKAP2 IL17A IL10 DEFB4A CLEC7A CARD9
32 bacterial pneumonia 30.0 IL22 IL17A IL10 DEFB4A
33 opportunistic mycosis 30.0 STAT1 SKAP2 IL17RA IL17F IL17A IL10
34 psoriatic arthritis 29.9 TRAF3IP2 IL22 IL17RA IL17A IL10
35 inflammatory bowel disease 29.8 STAT1 IL22 IL17F IL17A IL10 DEFB4A
36 hyper ige recurrent infection syndrome 1 29.7 STAT1 IL22 IL17RC IL17RA IL17F IL17A
37 b cell deficiency 29.6 SH2D1A IL17A IL10
38 nail disease 29.4 TRAF3IP2 STAT1 IL22 IL17RC IL17RA IL17F
39 candidiasis, familial, 2 12.7
40 candidiasis, familial, 6 12.7
41 neonatal candidiasis 12.7
42 candidiasis, familial, 4 12.7
43 candidiasis, familial, 8 12.7
44 candidiasis, familial, 1 12.6
45 candidiasis, familial, 9 12.6
46 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 12.4
47 candidiasis, familial, 3 12.4
48 immunodeficiency 51 12.2
49 immunodeficiency 31c 12.2
50 candidal paronychia 12.1

Comorbidity relations with Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hydronephrosis
Intestinal Obstruction Paralytic Ileus
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Candidiasis:



Diseases related to Candidiasis

Symptoms & Phenotypes for Candidiasis

MGI Mouse Phenotypes related to Candidiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 AIRE APCS CARD9 CLEC7A IL10 IL17A
2 immune system MP:0005387 9.83 AIRE APCS CARD9 CHIT1 CLEC7A HSP90AA1
3 digestive/alimentary MP:0005381 9.8 AIRE CLEC7A IL10 IL17A IL17F STAT1
4 respiratory system MP:0005388 9.17 AIRE CLEC7A IL10 IL17A IL17F IL17RA

Drugs & Therapeutics for Candidiasis

Drugs for Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
2
Voriconazole Approved Phase 4 137234-62-9 71616
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
6
Dequalinium Approved, Investigational Phase 4 6707-58-0
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
17
Nevirapine Approved Phase 4 129618-40-2 4463
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
20
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
21
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
22
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
23
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
24 Sympathomimetics Phase 4
25 Adrenergic beta-Agonists Phase 4
26
Salmeterol xinafoate Phase 4 94749-08-3 56801
27 Fluticasone-Salmeterol Drug Combination Phase 4
28 Adrenergic Agonists Phase 4
29 Adrenergic Agents Phase 4
30 Cytochrome P-450 CYP3A Inhibitors Phase 4
31 Echinocandins Phase 4
32 Immunologic Factors Phase 4
33 Epinephryl borate Phase 4
34 Ionophores Phase 4
35 Dermatologic Agents Phase 4
36 Disinfectants Phase 4
37 Hydrocortisone hemisuccinate Phase 4
38 Hydrocortisone-17-butyrate Phase 4
39 Hydrocortisone 17-butyrate 21-propionate Phase 4
40 Anti-Inflammatory Agents Phase 4
41 Analgesics, Non-Narcotic Phase 4
42 Analgesics Phase 4
43 Respiratory System Agents Phase 4
44 Anti-Asthmatic Agents Phase 4
45 glucocorticoids Phase 4
46 Castor Phase 4
47
s 1 (combination) Phase 4
48 Sodium hypochlorite Phase 4
49 Eusol Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 325)
# Name Status NCT ID Phase Drugs
1 Diagnosis of Pulmonary Candidiasis Unknown status NCT00537888 Phase 4 fluconazole
2 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
3 A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
4 Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis Completed NCT01994096 Phase 4 Caspofungin
5 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
6 CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients Completed NCT00670657 Phase 4 AmBisome
7 Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
8 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
9 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients Completed NCT01734525 Phase 4 Anidulafungin
10 Micafungin (Mycamine®) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (MICADO). Completed NCT03102658 Phase 4 Micafungin
11 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
12 Pharmacokinetics of Anidulafungin (Ecalta ®) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery. Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
13 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
14 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
15 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
16 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
17 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
18 Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
19 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
20 Oral Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
21 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
22 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
23 Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing Completed NCT02407834 Phase 4
24 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
25 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
26 The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients Completed NCT01495039 Phase 4 Nystatin
27 A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
28 Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers Completed NCT01307930 Phase 4 Anidulafungin
29 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
30 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
31 A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus Completed NCT02443311 Phase 4 Pimecrolimus 1% cream;Betamethasone 17-valerate 0.1% cream
32 Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin) Recruiting NCT03906916 Phase 4 Micafungin
33 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
34 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
35 A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion. Recruiting NCT02309346 Phase 4 Clindamycin
36 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
37 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Not yet recruiting NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
38 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment) Terminated NCT01982071 Phase 4 Micafungin
39 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
40 Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses Terminated NCT01646580 Phase 4 ciclopirox
41 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 Terminated NCT00177749 Phase 4 Posaconazole
42 A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
43 Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates) Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
44 "A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ". Unknown status NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
45 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
46 Dysbiosis in the Vaginal Microbiota May be Associated With the Development of Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
47 Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations Completed NCT00689338 Phase 3 Anidulafungin;Fluconazole;Voriconazole
48 A Single Center, Open, Parallel, Comparative, Randomized Study of Micafungin (FK463) vs Fluconazole (Diflucan) in the Treatment of Invasive Candidiasis and Candidaemia (Protocol No: MCFGCAN-0301F-TW) Completed NCT00189709 Phase 3 Micafungin;fluconazole
49 Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial Completed NCT01773876 Phase 3 Micafungin;PLACEBO
50 A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia Completed NCT00105144 Phase 3 Micafungin;Caspofungin

Search NIH Clinical Center for Candidiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Flucytosine

Cochrane evidence based reviews: candidiasis

Genetic Tests for Candidiasis

Anatomical Context for Candidiasis

MalaCards organs/tissues related to Candidiasis:

40
Testes, Colon, Skin, Liver, T Cells, Bone, Brain

Publications for Candidiasis

Articles related to Candidiasis:

(show top 50) (show all 14782)
# Title Authors PMID Year
1
Candidemia and invasive candidiasis in adults: A narrative review. 61 52
27394927 2016
2
T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. 61 52
26371384 2016
3
[HBD-1 and hBD-2 are expressed in cervico-vaginal lavage in female genital tract due to microbial infections]. 54 61
20476598 2010
4
Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. 54 61
19196253 2009
5
Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. 54 61
19037923 2008
6
Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. 54 61
18606876 2008
7
Efungumab and caspofungin: pre-clinical data supporting synergy. 54 61
18299636 2008
8
[Preliminary evaluation of a vaginal cream containing lactoferrin in the treatment of vulvovaginal candidosis]. 54 61
18487962 2008
9
The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression. 54 61
18292755 2008
10
Recurrent herpes simplex virus infection in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy associated with L29P and IVS9-1G>C compound heterozygous autoimmune regulator gene mutations. 54 61
17547716 2007
11
Production of hybrid phage displaying secreted aspartyl proteinase epitope of Candida albicans and its application for the diagnosis of disseminated candidiasis. 54 61
17472610 2007
12
Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. 54 61
16940535 2006
13
Ets transcription factors regulate AIRE gene promoter. 54 61
16890195 2006
14
Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. 54 61
16784312 2006
15
Disruption of immunological tolerance: role of AIRE gene in autoimmunity. 54 61
16431348 2006
16
Immunodeficiencies with autoimmune consequences. 54 61
16682278 2006
17
The monopartite nuclear localization signal of autoimmune regulator mediates its nuclear import and interaction with multiple importin alpha molecules. 54 61
16403019 2006
18
Functional analysis of SAND mutations in AIRE supports dominant inheritance of the G228W mutation. 54 61
16114041 2005
19
Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. 54 61
15963364 2005
20
AIRE and immunological tolerance: insights from the study of autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy. 54 61
15640689 2004
21
Autoimmune regulator induced changes in the gene expression profile of human monocyte-dendritic cell-lineage. 54 61
15482854 2004
22
Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. 54 61
15378761 2004
23
Potential usefulness of bovine lactoferrrin for adjunctive immunotherapy for mucosal Candida infections. 54 61
15222472 2004
24
Recombinant antibodies: a natural partner in combinatorial antifungal therapy. 54 61
15040939 2004
25
Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis. 54 61
14659657 2003
26
Life-threatening autoimmunity with diabetes: management with an insulin pump. 54 61
14655274 2003
27
Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. 54 61
12870130 2003
28
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. 54 61
12821470 2003
29
The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. 54 61
12761103 2003
30
Characterization of regulatory elements and methylation pattern of the autoimmune regulator (AIRE) promoter. 54 61
12651856 2003
31
A novel AIRE mutation in an APECED patient with candidiasis, adrenal failure, hepatitis, diabetes mellitus and osteosclerosis. 54 61
12784192 2003
32
New sensitive method for the measurement of lysozyme and lactoferrin to explore mucosal innate immunity. Part II: time-resolved immunofluorometric assay used in HIV patients with oral candidiasis. 54 61
12666997 2003
33
Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. 54 61
12542742 2002
34
A novel missense mutation of AIRE gene in a patient with autoimmune polyendocrinopathy, candidiasis and ectodermal dystrophy (APECED), accompanied with progressive muscular atrophy: case report and review of the literature in Japan. 54 61
12625412 2002
35
Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. 54 61
12439202 2002
36
The secreted aspartic proteinases as a new target in the therapy of candidiasis. 54 61
12182226 2002
37
Secreted aspartic proteases as virulence factors of Candida species. 54 61
12437091 2002
38
Evidence for differential expression of candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. 54 61
11930319 2002
39
Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. 54 61
11807692 2002
40
Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. 54 61
11936455 2002
41
Aspartyl proteinases of Candida albicans and their role in pathogenicity. 54 61
11556759 2001
42
HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. 54 61
11476984 2001
43
Antifungal antibodies: a new approach to the treatment of systemic candidiasis. 54 61
11566001 2001
44
Subcellular location and expression pattern of autoimmune regulator (Aire), the mouse orthologue for human gene defective in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED). 54 61
11156688 2001
45
Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. 54 61
10733678 2000
46
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. 54 61
10395861 1999
47
Clinical strains of Candida albicans express the surface antigen glyceraldehyde 3-phosphate dehydrogenase in vitro and in infected tissues. 54 61
10219595 1999
48
Chromosomal localization and complete genomic sequence of the murine autoimmune regulator gene (Aire). 54 61
10593569 1999
49
A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type 1. 54 61
9837820 1998
50
Chronic vaginal candidiasis responsive to biotin therapy in a carrier of biotinidase deficiency. 54 61
9764646 1998

Variations for Candidiasis

Expression for Candidiasis

Search GEO for disease gene expression data for Candidiasis.

Pathways for Candidiasis

Pathways related to Candidiasis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 STAT1 SH2D1A IL22 IL17RC IL17RA IL17F
2
Show member pathways
13.23 STAT1 IL22 IL17RC IL17RA IL17A IL10
3
Show member pathways
13.12 STAT1 IL22 IL17RC IL17RA IL17F IL17A
4
Show member pathways
12.66 STAT1 IL22 IL17A IL10 HSP90AA1
5
Show member pathways
12.38 STAT1 IL22 IL17F IL17A IL10 HSP90AA1
6 12.35 STAT1 SH2D1A IL17A IL10 CARD9
7 12.05 STAT1 HSP90AA1 DEFB4A CARD9
8 12.03 STAT1 IL10 CLEC7A CARD9
9
Show member pathways
12 STAT1 IL10 CLEC7A CARD9
10
Show member pathways
11.77 STAT1 IL22 IL17F IL17A IL10
11 11.61 STAT1 IL17F IL17A IL10 HSP90AA1
12 11.59 IL22 IL17A IL10
13
Show member pathways
11.5 TRAF3IP2 IL17RC IL17RA IL17F IL17A HSP90AA1
14
Show member pathways
11.32 TRAF3IP2 IL17RC IL17RA IL17F IL17A

GO Terms for Candidiasis

Cellular components related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 IL22 IL17RA IL17F IL17A IL10 HTN3

Biological processes related to Candidiasis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 IL17A IL10 DEFB4A CHIT1 AIRE
2 inflammatory response GO:0006954 9.89 IL22 IL17F IL17A IL10 CLEC7A
3 cytokine-mediated signaling pathway GO:0019221 9.7 STAT1 IL22 IL17RC IL17F IL17A IL10
4 humoral immune response GO:0006959 9.69 TRAF3IP2 SH2D1A AIRE
5 positive regulation of interleukin-6 secretion GO:2000778 9.58 IL17RC IL17F IL17A
6 defense response to fungus GO:0050832 9.56 IL17RC IL17RA IL17A HTN3
7 chaperone-mediated protein complex assembly GO:0051131 9.54 HSP90AA1 APCS
8 granulocyte chemotaxis GO:0071621 9.48 IL17RC IL17RA
9 positive regulation of interleukin-23 production GO:0032747 9.46 IL17RA IL17A
10 regulation of interleukin-6 biosynthetic process GO:0045408 9.43 IL17F CARD9
11 fibroblast activation GO:0072537 9.37 IL17RA IL17A
12 regulation of interleukin-2 biosynthetic process GO:0045076 9.32 IL17F CARD9
13 interleukin-17-mediated signaling pathway GO:0097400 9.26 IL17RC IL17RA IL17F IL17A
14 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.02 IL17RC IL17RA IL17F IL17A CLEC7A

Molecular functions related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL22 IL17F IL17A IL10
2 interleukin-17 receptor activity GO:0030368 8.62 IL17RC IL17RA

Sources for Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....